Study of Magrolimab Combinations in Participants With Myeloid Malignancies

NCT04778410 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

54

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision to terminate the study.

Conditions

Myeloid Malignancies

Interventions

DRUG: Magrolimab
DRUG: Azacitidine
DRUG: Venetoclax
DRUG: Mitoxantrone
DRUG: Etoposide
DRUG: Cytarabine
DRUG: CC-486

Sponsor

Gilead Sciences